Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Venture&Growth
Affimed
Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer. Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing
Venture&Growth
Withings
French Healthtech company commercializing personal health devices.
Venture&Growth
Mainstay Medical
Mainstay Medical is a Irish medical device company that develops and commercializes an implantable restorative neurostimulation system (ReActiv8) to treat people with disabling chronic low back pain. Mainstay Medical is commercializing their therapy in the US, Australia, Germany and the
